PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), Provides Studies, Clinical Trials Update

November 4, 2021 12:24:58

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has released an update on strategic initiatives related to its MINDCURE Research and MINDCURE Technology divisions. According to the company, its synthetic ibogaine efforts, which were announced in March 2021, include the application for two patents and the initiation of production of Good Laboratory Practice (“GLP”) ibogaine leading to the production of Good Manufacturing Practice (“GMP”) ibogaine. The company is on schedule to provide GLP supply to research partners by Q2 2022. The company is in the process of preparing to ship ibogaine drug material to its preclinical research partner. In addition, MINDCURE has wrapped up its draft research protocol for the use of MDMA and psychotherapy to treat female sexual hypoactive desire disorder. The company anticipates scheduling a pre-IND meeting with the FDA in the first quarter of 2022 with a phase 2 trial expected to commence by third quarter 2022. Regarding iSTRYM, its digital therapeutics (“DTx”) technology, MINDCURE noted that it has released the minimum viable product (“MVP”) of the tech into partner clinics across North America, exceeded its target and timeline of 10 clinics by the end of 2021. “We are proud to report that MINDCURE’s core research programs are progressing rapidly, showcasing our disciplined commitment to advancing MINDCURE’s drug research and commercial production programs,” said Mind Cure Health president and CEO Kelsey Ramsden in the press release. “Concurrently, we maintain a focus on identifying opportunities to expand our drug-development pipeline.”

To view the full press release, visit

About Mind Cure Health Inc.

MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.